ARTICLE | Clinical News
SU5416: Began Phase I/II studies
May 10, 1999 7:00 AM UTC
Sugen Inc. (SUGN), South San Francisco, Calif. Product: SU5416 Business: Cancer Therapeutic category: Angiogenesis Target: Flk-1/KDR receptor Description: Small molecule inhibitor of the Flk-1/KDR rec...